Urokinase-type plasminogen activator receptor: a beacon of malignancy?
OA: closed
AI-generated summary
This paper highlights the diagnostic challenge of distinguishing benign from malignant pelvic masses in women and emphasizes the need for reliable serum biomarkers to improve patient referral and early detection strategies.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-20T09:27:46.357103+00:00